logo
Share SHARE
FONT-SIZE Plus   Neg

Auxilium Pharma, GlaxoSmithKline Sign Agreement For Co-promotion Of Testim 1%

Auxilium Pharmaceuticals, Inc. (AUXL) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (GSK, GSK.L), announced that they have entered into an agreement for the co-promotion of Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

As per the agreement terms, Auxilium granted GSK the exclusive right to co-promote the sale of Testim with Auxilium in the U.S. through September 30, 2015. GSK will promote Testim using a sizeable established field sales force which has relationships with current Testosterone Replacement Therapy prescribers, particularly primary care physicians, in the U.S.

Both the companies have agreed on a baseline revenue forecast for Testim through September 30, 2015, and GSK will be compensated to the extent that Testim net sales exceed this baseline. In addition, in certain circumstances, Auxilium will pay GSK specified tail payments following the term of the agreement. The GSK sales force is expected to begin promoting Testim to physicians early in the third quarter 2012.

In a separate press release, Auxilium Pharma said it is raising its full year 2012 revenue guidance to a range of $293 million to $315 million from prior forecast of $283 million- $305 million.

The company also said it is reducing its full-year guidance for net loss to a range of $5 to $10 million from the previous range of $5 to $15 million.

Analysts polled by Thomson Reuters expect the company to report loss of $0.27 per share, on revenues of $299.16 million. Analysts' estimates typically exclude special items.

"As a result of this morning's announcement concerning the Testim U.S. co-promotion agreement, we are increasing Testim revenue guidance and trimming net loss guidance for 2012," said Jim Fickenscher, Chief Financial Officer of Auxilium. "While we have not changed our previously stated guidance for Selling, General & Administrative expense, it is likely that we will be near the top end of the range."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Philips Electronics NV were gaining around 4 percent in the early morning trading in Amsterdam after the Dutch consumer electronics giant reported Monday that its second-quarter net income from continuing operations increased with higher sales and orders. Net income, meanwhile, declined with lower income from discontinued operations. Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely.
comments powered by Disqus
Follow RTT